The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Stimulating an immune response through bavituximab in a phase III lung cancer study.
David E. Gerber
Honoraria - Peregrine Pharmaceuticals
Research Funding - Peregrine Pharmaceuticals
Joseph Shan
No relevant relationships to disclose
Ulrich Keilholz
No relevant relationships to disclose
David R. Spigel
No relevant relationships to disclose
Leora Horn
No relevant relationships to disclose
Rebecca Suk Heist
No relevant relationships to disclose
Rachel E. Sanborn
No relevant relationships to disclose
Paul N. Mainwaring
No relevant relationships to disclose
Chandra Prakash Belani
No relevant relationships to disclose
Martin J. Edelman
No relevant relationships to disclose